[HTML][HTML] Lymecycline reverses acquired EGFR-TKI resistance in non–small-cell lung cancer by targeting GRB2
Y Chen, J Wu, H Yan, Y Cheng, Y Wang, Y Yang… - Pharmacological …, 2020 - Elsevier
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were first-line
treatments for NSCLC patients with EGFR-mutations. However, about 30% of responders …
treatments for NSCLC patients with EGFR-mutations. However, about 30% of responders …
Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2
Y Chen, J Wu, H Yan, Y Cheng… - Pharmacological …, 2020 - pubmed.ncbi.nlm.nih.gov
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were first-line
treatments for NSCLC patients with EGFR-mutations. However, about 30% of responders …
treatments for NSCLC patients with EGFR-mutations. However, about 30% of responders …
Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Y Chen, J Wu, H Yan, Y Cheng, Y Wang… - Pharmacological …, 2020 - europepmc.org
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were first-line
treatments for NSCLC patients with EGFR-mutations. However, about 30% of responders …
treatments for NSCLC patients with EGFR-mutations. However, about 30% of responders …